# OnCo record nct06081959 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06081959/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06081959", "NCT06081959" ;
  schema:name "Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer"@en ;
  schema:description "A phase 3 trial of Eribulin, Capecitabine, Gemcitabine and Vinorelbine in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06081959/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06081959> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2023-10-31" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:drugs <https://onco.cc/drugs/eribulin/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/vinorelbine/> ;
  onco:companies <https://onco.cc/companies/kelun-biotech/> .